Free CME from PeerView


Pathology CME

Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Navigating Complex Decisions at the Intersection of Local and Systemic Management of Early Breast Cancer
Laura S. Dominici, MD, FACS
March 24, 2023
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Harnessing the Power of Immunotherapy in Resectable Melanoma: Guidance for Delivering Effective Adjuvant and Neoadjuvant Strategies
Jennifer Wargo, MD, MMSc
March 22, 2023
Credits: 1.0 CME / CC
PVI, PeerView Institute for Medical Education
Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies: Practical Strategies for Biomarker Testing and Pathologic Response Assessment
Tricia Cottrell, MD, MPH / Lynette M. Sholl, MD
March 14, 2023
Credits: 1.5 CME / MOC / CC
PVI, PeerView Institute for Medical Education
A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and Treatment
Stuart J. Schnitt, MD
March 13, 2023
Credits: 1.5 CME / CC
PVI, PeerView Institute for Medical Education
The Precision Team in AML: Exploring Pathologist-Informed Clinical Decisions in Challenging AML Settings
Naval Daver, MD / Joseph D. Khoury, MD, FCAP
March 13, 2023
Credits: 1.0 CME / MOC / CC
PVI, PeerView Institute for Medical Education
Seizing the Precision Care Moment in MDS: Collaborative Strategies for Accurate Diagnoses and Risk-Adapted Treatment
Rami Komrokji, MD
March 13, 2023
Credits: 1.0 CME / CC
PVI, PeerView Institute for Medical Education
Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment
Janis Taube, MD, MSc
March 02, 2023
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Perfecting Precision in Modern NSCLC Practice: Are You Optimally Integrating Biomarker-Driven Therapy?
Stephen V. Liu, MD
February 27, 2023
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Refining Precision Decisions in NSCLC With Common and Less Common EGFR Mutations: Navigating Testing and Treatment Throughout the Disease Continuum
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
February 23, 2023
Credits: 1.0 CME / MOC / CC / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLC
Nathan A. Pennell, MD, PhD, FASCO
January 30, 2023
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary Alliances
Nasser Altorki, MD / Jonathan D. Spicer, MD, PhD, FRCSC
January 21, 2023
Credits: 1.5 CME / MOC
PVI, PeerView Institute for Medical Education
Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other Cancers
Vivek Subbiah, MD
January 20, 2023
Credits: 1.5 CME / MOC
PVI, PeerView Institute for Medical Education
Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients
Professor Aleix Prat, MD, PhD
September 29, 2022
Credits: 0.5 CME / MOC
PVI, PeerView Institute for Medical Education
Optimizing NTRK Fusion Testing and TRK Inhibition in Thyroid Cancer: Team-Based Approaches for Enhanced Outcomes
Marcia S. Brose, MD, PhD, FASCO
September 26, 2022
Credits: 1.0 CME / MOC / NCPD
Medical Learning Institute, Inc.
Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC
Alexander Drilon, MD
September 02, 2022
Credits: 1.5 CME / MOC
PVI, PeerView Institute for Medical Education
Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents
Elena Elez, MD, PhD
July 01, 2022
Credits: 1.5 CME / MOC
PVI, PeerView Institute for Medical Education
Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care
Stephen V. Liu, MD
June 05, 2022
Credits: 1.5 CME / MOC
PVI, PeerView Institute for Medical Education
The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient Care
Robert I. Haddad, MD
June 05, 2022
PVI, PeerView Institute for Medical Education
Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers
Prof. Solange Peters, MD, PhD
April 10, 2022
Medical Learning Institute, Inc.
Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do
Kurt A. Schalper, MD, PhD
March 22, 2022
Purdue University
Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease?
Liana G. Apostolova, MS, MD, FAAN
March 18, 2022
Stephen V. Liu, MD
PVI, PeerView Institute for Medical Education
Visual Exploration of the Possibilities for Macrocyclic TKIs in Treatment-Naive and Pretreated Fusion-Positive NSCLC and Other Tumors
Stephen V. Liu, MD
February 18, 2022
Michael Heinrich, MD
Medical Learning Institute, Inc.
Optimally Sequencing Modern TKIs in GIST: Expert Perspectives From an Interprofessional Sarcoma Team
Michael Heinrich, MD
January 13, 2022
Medical Learning Institute, Inc.
New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor Therapy
Sara M. Tolaney, MD, MPH
December 28, 2021
Medical Learning Institute, Inc.
Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings
Lynette M. Sholl, MD
October 29, 2021
Medical Learning Institute, Inc.
Evolving Standards in Biomarker Testing, Scoring, and Results Interpretation Driven by the Broadening Role of Cancer Immunotherapy
Kurt A. Schalper, MD, PhD
September 29, 2021
Credits: 1 CME / MOC / CC / NCPD
PVI, PeerView Institute for Medical Education
Maximizing the Potential of Immunotherapy in Multimodal Management of Unresectable Stage III NSCLC: Collaboration Is Crucial, Patient Selection Is Paramount, Close Monitoring Is Critical
September 02, 2021
Medical Learning Institute, Inc.
The Expanding Advanced Ovarian Cancer Treatment Palette: Candid Conversations on Bringing PARP Inhibitors Into Clinical Practice
Deborah K. Armstrong, MD
July 06, 2021
Medical Learning Institute, Inc.
Innovative Immunotherapy in Advanced Basal Cell Carcinoma: Evolving Science, Key Clinical Evidence, and Implications for Multidisciplinary Management
Karl D. Lewis, MD
June 25, 2021

Upcoming Live Events

Education Collections

More Education Collections

Recent CME Podcast

More Podcasts from PeerView